LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain
Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
Turning AI skeptics into AI advocates through high-integrity data
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development